Quarterly report · Q2
8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥679.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥620.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥6.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥740.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥695.9bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥495.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥245.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥240.7bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥102.1bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥97.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥97.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥407m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥51.01 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.39 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.84 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥46.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.62 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥850m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥878m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥478m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥654.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥631.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥23.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥782m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥708.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥679.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥996m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.5bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥45.4bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥819m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥312m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥597.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥572.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥24.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥667m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥100m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥649.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥620.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 580
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1QuarterInstant | 97124000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 97855000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 572576000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 45444000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 819000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 2004000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 620845000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 620845000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 24407000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 5000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 3209000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 667000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 28288000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -28288000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 596983000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 45450000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 4028000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 2672000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 649134000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -28288000000 | JPY |
| Net sales | Prior1YTDDuration | 620845000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 1130000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 1317000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 312000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 100000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2860000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -996000000 | JPY |
| Operating income | Prior1YTDDuration | 1863000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 631009000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 45085000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 1097000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 2527000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 679719000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 679719000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 23810000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 3741000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 782000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 28338000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -28338000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsRetailReportableSegmentsMember | 654820000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02608-000DispensingPharmacyReportableSegmentsMember | 45089000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02608-000MedicalProductsManufacturingAndSalesReportableSegmentMember | 4838000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E02608-000OtherRelatedBusinessReportableSegmentMember | 3309000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 708058000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -28338000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |